Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 82.38% | -28.07% | -5.05% | -42.69% | -29.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.42% | -33.76% | -29.63% | -32.84% | -13.72% |
| Operating Income | -40.42% | 33.76% | 29.63% | 32.84% | 13.72% |
| Income Before Tax | -32.79% | 25.73% | 18.13% | 22.23% | -14.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.79% | 25.73% | 18.13% | 22.23% | -14.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.79% | 25.73% | 18.13% | 22.23% | -14.25% |
| EBIT | -40.42% | 33.76% | 29.63% | 32.84% | 13.72% |
| EBITDA | -41.44% | 33.85% | 29.97% | 33.12% | 13.57% |
| EPS Basic | -3.74% | 57.31% | 57.72% | 62.49% | 37.07% |
| Normalized Basic EPS | -3.71% | 57.30% | 57.73% | 62.48% | 37.07% |
| EPS Diluted | -3.74% | 57.31% | 57.72% | 62.49% | 37.07% |
| Normalized Diluted EPS | -3.71% | 57.30% | 57.73% | 62.48% | 37.07% |
| Average Basic Shares Outstanding | 28.01% | 74.00% | 93.66% | 107.31% | 81.57% |
| Average Diluted Shares Outstanding | 28.01% | 74.00% | 93.66% | 107.31% | 81.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |